| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiration, Artificial | 16 | 2014 | 352 | 2.950 |
Why?
|
| Pemphigus | 6 | 2021 | 14 | 2.860 |
Why?
|
| Intensive Care Units | 16 | 2014 | 395 | 2.700 |
Why?
|
| Critical Illness | 14 | 2014 | 306 | 2.630 |
Why?
|
| Muscle Weakness | 6 | 2014 | 60 | 1.990 |
Why?
|
| Polyneuropathies | 4 | 2014 | 27 | 1.550 |
Why?
|
| Critical Care | 12 | 2014 | 380 | 1.520 |
Why?
|
| Immunoglobulin G | 4 | 2021 | 464 | 1.390 |
Why?
|
| Conscious Sedation | 7 | 2014 | 69 | 1.000 |
Why?
|
| Autoantibodies | 4 | 2021 | 268 | 0.970 |
Why?
|
| Muscle Relaxants, Central | 2 | 2013 | 10 | 0.920 |
Why?
|
| Neuromuscular Blockade | 2 | 2013 | 26 | 0.900 |
Why?
|
| Length of Stay | 7 | 2014 | 732 | 0.860 |
Why?
|
| Desmoglein 3 | 2 | 2020 | 5 | 0.860 |
Why?
|
| Desmoglein 1 | 2 | 2020 | 7 | 0.860 |
Why?
|
| Hypnotics and Sedatives | 5 | 2014 | 131 | 0.830 |
Why?
|
| Receptors, Fc | 2 | 2021 | 32 | 0.780 |
Why?
|
| Patient Transfer | 3 | 2012 | 94 | 0.750 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2020 | 12 | 0.730 |
Why?
|
| Prednisone | 3 | 2020 | 258 | 0.680 |
Why?
|
| Receptors, Nicotinic | 1 | 2020 | 131 | 0.670 |
Why?
|
| Thoracic Diseases | 2 | 2014 | 27 | 0.540 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 3 | 2024 | 6 | 0.510 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 967 | 0.510 |
Why?
|
| Humans | 65 | 2024 | 89073 | 0.510 |
Why?
|
| Skin | 5 | 2020 | 581 | 0.490 |
Why?
|
| Benzodiazepines | 2 | 2012 | 67 | 0.480 |
Why?
|
| Infliximab | 1 | 2015 | 159 | 0.470 |
Why?
|
| Dermatologic Agents | 1 | 2015 | 73 | 0.460 |
Why?
|
| Pulmonary Medicine | 1 | 2014 | 46 | 0.460 |
Why?
|
| Interactive Ventilatory Support | 1 | 2013 | 5 | 0.460 |
Why?
|
| Hospital Mortality | 4 | 2015 | 386 | 0.460 |
Why?
|
| Inpatients | 2 | 2016 | 310 | 0.450 |
Why?
|
| Delirium | 3 | 2014 | 72 | 0.450 |
Why?
|
| Respiratory Rate | 1 | 2013 | 20 | 0.450 |
Why?
|
| Ventilator-Induced Lung Injury | 1 | 2013 | 31 | 0.450 |
Why?
|
| Deep Sedation | 1 | 2013 | 15 | 0.450 |
Why?
|
| Life Support Care | 2 | 2012 | 50 | 0.440 |
Why?
|
| Analgesia | 1 | 2013 | 58 | 0.430 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 599 | 0.430 |
Why?
|
| Middle Aged | 36 | 2024 | 25865 | 0.420 |
Why?
|
| Hospitals, Chronic Disease | 1 | 2012 | 2 | 0.410 |
Why?
|
| Aged | 32 | 2024 | 19078 | 0.410 |
Why?
|
| Intermediate Care Facilities | 1 | 2011 | 2 | 0.400 |
Why?
|
| Health Services Research | 2 | 2012 | 137 | 0.390 |
Why?
|
| Male | 40 | 2024 | 42254 | 0.380 |
Why?
|
| Skilled Nursing Facilities | 1 | 2011 | 41 | 0.380 |
Why?
|
| Physical Therapy Modalities | 4 | 2014 | 83 | 0.370 |
Why?
|
| Female | 39 | 2024 | 46014 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 4 | 2014 | 1043 | 0.370 |
Why?
|
| Shock, Septic | 2 | 2013 | 104 | 0.360 |
Why?
|
| Analgesics, Opioid | 2 | 2012 | 442 | 0.360 |
Why?
|
| Biomedical Research | 2 | 2012 | 398 | 0.360 |
Why?
|
| Adult | 28 | 2024 | 26508 | 0.350 |
Why?
|
| Multiple Organ Failure | 1 | 2010 | 53 | 0.340 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2009 | 29 | 0.340 |
Why?
|
| Recovery of Function | 1 | 2011 | 292 | 0.340 |
Why?
|
| Risk Factors | 10 | 2024 | 5466 | 0.340 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 108 | 0.340 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2010 | 94 | 0.330 |
Why?
|
| Rituximab | 2 | 2020 | 119 | 0.330 |
Why?
|
| Tidal Volume | 1 | 2008 | 54 | 0.320 |
Why?
|
| Inhalation | 1 | 2008 | 31 | 0.320 |
Why?
|
| Analgesics | 1 | 2009 | 119 | 0.320 |
Why?
|
| Patient Discharge | 1 | 2011 | 320 | 0.310 |
Why?
|
| Hysterectomy | 1 | 2009 | 151 | 0.310 |
Why?
|
| Extravascular Lung Water | 1 | 2008 | 5 | 0.310 |
Why?
|
| Physician Executives | 1 | 2008 | 22 | 0.310 |
Why?
|
| Societies, Medical | 1 | 2012 | 570 | 0.300 |
Why?
|
| Dermatitis Herpetiformis | 3 | 2006 | 9 | 0.300 |
Why?
|
| Lymph Node Excision | 1 | 2009 | 220 | 0.300 |
Why?
|
| Patient Admission | 1 | 2008 | 114 | 0.290 |
Why?
|
| Young Adult | 8 | 2021 | 6289 | 0.290 |
Why?
|
| Adrenal Insufficiency | 1 | 2006 | 23 | 0.280 |
Why?
|
| Muscular Diseases | 1 | 2007 | 64 | 0.280 |
Why?
|
| E-Selectin | 1 | 2006 | 30 | 0.270 |
Why?
|
| Interleukin-8 | 1 | 2006 | 86 | 0.270 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 385 | 0.270 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2009 | 295 | 0.270 |
Why?
|
| Occupational Therapy | 3 | 2010 | 16 | 0.270 |
Why?
|
| Early Ambulation | 3 | 2010 | 25 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2006 | 699 | 0.260 |
Why?
|
| Myocardial Ischemia | 1 | 2007 | 161 | 0.260 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 783 | 0.240 |
Why?
|
| Brain Diseases | 1 | 2006 | 185 | 0.240 |
Why?
|
| Heart Arrest | 3 | 2012 | 279 | 0.230 |
Why?
|
| Retrospective Studies | 13 | 2024 | 9003 | 0.230 |
Why?
|
| Endothelial Cells | 1 | 2006 | 459 | 0.220 |
Why?
|
| Respiratory Insufficiency | 3 | 2010 | 162 | 0.210 |
Why?
|
| Pemphigoid, Bullous | 2 | 1999 | 12 | 0.200 |
Why?
|
| Treatment Outcome | 9 | 2024 | 8203 | 0.200 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 362 | 0.200 |
Why?
|
| Autoantigens | 2 | 2020 | 129 | 0.200 |
Why?
|
| Bed Rest | 3 | 2010 | 5 | 0.200 |
Why?
|
| Vital Signs | 2 | 2012 | 38 | 0.200 |
Why?
|
| Scleroderma, Localized | 1 | 2020 | 9 | 0.190 |
Why?
|
| Iron-Binding Proteins | 1 | 2020 | 15 | 0.180 |
Why?
|
| Propofol | 2 | 2014 | 92 | 0.180 |
Why?
|
| Scleroderma, Systemic | 1 | 2020 | 52 | 0.180 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2021 | 201 | 0.180 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2020 | 56 | 0.180 |
Why?
|
| Survivors | 2 | 2011 | 233 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 975 | 0.160 |
Why?
|
| Iodide Peroxidase | 1 | 2020 | 205 | 0.160 |
Why?
|
| Sepsis | 2 | 2014 | 319 | 0.160 |
Why?
|
| Logistic Models | 5 | 2014 | 1212 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2011 | 229 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 360 | 0.150 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2017 | 10 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2021 | 948 | 0.150 |
Why?
|
| Conjunctival Diseases | 1 | 2017 | 7 | 0.150 |
Why?
|
| Spectrum Analysis | 1 | 2018 | 119 | 0.150 |
Why?
|
| Conjunctiva | 1 | 2017 | 19 | 0.150 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 61 | 0.150 |
Why?
|
| Adjuvants, Immunologic | 1 | 2018 | 168 | 0.150 |
Why?
|
| Optical Imaging | 1 | 2018 | 50 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2014 | 2863 | 0.140 |
Why?
|
| Adolescent | 6 | 2021 | 9237 | 0.140 |
Why?
|
| United States | 5 | 2016 | 6957 | 0.140 |
Why?
|
| Dermatomycoses | 1 | 2015 | 9 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2018 | 1855 | 0.130 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 579 | 0.130 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 153 | 0.130 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 6777 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1837 | 0.130 |
Why?
|
| Hospitalization | 3 | 2016 | 876 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 60 | 0.130 |
Why?
|
| Cytokines | 1 | 1999 | 802 | 0.130 |
Why?
|
| Wakefulness | 2 | 2012 | 135 | 0.120 |
Why?
|
| Immobilization | 1 | 2014 | 21 | 0.120 |
Why?
|
| Health Care Costs | 1 | 2016 | 235 | 0.120 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2014 | 48 | 0.120 |
Why?
|
| Canada | 1 | 2014 | 208 | 0.110 |
Why?
|
| Fentanyl | 1 | 2014 | 67 | 0.110 |
Why?
|
| Immune System Diseases | 1 | 2014 | 27 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2011 | 225 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2014 | 180 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 1715 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2014 | 172 | 0.110 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 139 | 0.110 |
Why?
|
| Dermatology | 3 | 2003 | 40 | 0.110 |
Why?
|
| Bacteremia | 1 | 2014 | 102 | 0.110 |
Why?
|
| Vasopressins | 1 | 2013 | 50 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2014 | 310 | 0.110 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 56 | 0.110 |
Why?
|
| Norepinephrine | 1 | 2013 | 170 | 0.110 |
Why?
|
| Remote Consultation | 2 | 2003 | 16 | 0.100 |
Why?
|
| Prognosis | 3 | 2014 | 3773 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2013 | 590 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2018 | 4273 | 0.100 |
Why?
|
| Withholding Treatment | 1 | 2012 | 117 | 0.100 |
Why?
|
| Triage | 1 | 2012 | 111 | 0.100 |
Why?
|
| Work | 1 | 2011 | 15 | 0.100 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 269 | 0.090 |
Why?
|
| Catheterization, Central Venous | 2 | 2009 | 115 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 275 | 0.090 |
Why?
|
| Time Factors | 5 | 2012 | 5320 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 1096 | 0.090 |
Why?
|
| After-Hours Care | 1 | 2010 | 8 | 0.090 |
Why?
|
| Night Care | 1 | 2010 | 9 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 342 | 0.090 |
Why?
|
| Convalescence | 1 | 2010 | 12 | 0.090 |
Why?
|
| Pneumonia | 1 | 2011 | 182 | 0.090 |
Why?
|
| Anniversaries and Special Events | 1 | 2010 | 14 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2010 | 120 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3657 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2012 | 305 | 0.080 |
Why?
|
| Chicago | 2 | 2011 | 1423 | 0.080 |
Why?
|
| Glucocorticoids | 2 | 2024 | 357 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2014 | 1533 | 0.080 |
Why?
|
| Insulin Resistance | 2 | 2014 | 353 | 0.080 |
Why?
|
| Exercise Therapy | 1 | 2009 | 81 | 0.080 |
Why?
|
| Animals | 3 | 2013 | 27324 | 0.080 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 37 | 0.080 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 225 | 0.080 |
Why?
|
| Neck | 1 | 2009 | 103 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2012 | 1706 | 0.080 |
Why?
|
| Sleep | 1 | 2012 | 452 | 0.080 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 51 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 433 | 0.070 |
Why?
|
| Pulmonary Edema | 1 | 2008 | 50 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.070 |
Why?
|
| ROC Curve | 4 | 2012 | 781 | 0.070 |
Why?
|
| Movement | 1 | 2009 | 307 | 0.070 |
Why?
|
| Patient-Centered Care | 1 | 2009 | 207 | 0.070 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 643 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2011 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2008 | 280 | 0.070 |
Why?
|
| Butyrophenones | 1 | 2006 | 5 | 0.070 |
Why?
|
| Central Venous Pressure | 1 | 2006 | 26 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2007 | 64 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 2006 | 83 | 0.070 |
Why?
|
| L-Selectin | 1 | 2006 | 16 | 0.070 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 233 | 0.070 |
Why?
|
| Jugular Veins | 1 | 2006 | 74 | 0.070 |
Why?
|
| Body Weight | 1 | 2008 | 452 | 0.070 |
Why?
|
| Decision Making | 2 | 2012 | 665 | 0.070 |
Why?
|
| Hypercapnia | 1 | 2006 | 44 | 0.070 |
Why?
|
| Endosonography | 1 | 2007 | 98 | 0.070 |
Why?
|
| Transglutaminases | 1 | 2006 | 40 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 73 | 0.070 |
Why?
|
| Gastroenteritis | 1 | 2006 | 26 | 0.070 |
Why?
|
| Biomarkers | 2 | 2006 | 1755 | 0.070 |
Why?
|
| Robotics | 1 | 2009 | 269 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2014 | 848 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 145 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2005 | 72 | 0.070 |
Why?
|
| Physical Examination | 1 | 2006 | 148 | 0.070 |
Why?
|
| Coma | 1 | 2006 | 47 | 0.070 |
Why?
|
| Physicians | 1 | 2012 | 689 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2012 | 2291 | 0.060 |
Why?
|
| Lung | 1 | 2011 | 1258 | 0.060 |
Why?
|
| Monocytes | 1 | 2005 | 218 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2005 | 261 | 0.060 |
Why?
|
| Pain | 1 | 2006 | 400 | 0.060 |
Why?
|
| Affect | 1 | 2005 | 387 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2007 | 548 | 0.050 |
Why?
|
| Visual Acuity | 1 | 2024 | 198 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 833 | 0.050 |
Why?
|
| Prevalence | 1 | 2007 | 1240 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2362 | 0.050 |
Why?
|
| Dapsone | 1 | 1982 | 10 | 0.050 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 1982 | 18 | 0.050 |
Why?
|
| Quality of Life | 1 | 2011 | 1662 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2005 | 321 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2009 | 771 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2002 | 40 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2014 | 150 | 0.050 |
Why?
|
| Recurrence | 1 | 2024 | 1140 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1982 | 210 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 306 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2020 | 145 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2012 | 493 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 1999 | 36 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 1488 | 0.040 |
Why?
|
| Child | 3 | 2006 | 7149 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1999 | 56 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 1999 | 38 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2002 | 341 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 1999 | 130 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 1999 | 313 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 1999 | 251 | 0.040 |
Why?
|
| Eosinophils | 1 | 1999 | 194 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 779 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 1999 | 426 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 2014 | 0.040 |
Why?
|
| Keratosis | 1 | 1997 | 21 | 0.040 |
Why?
|
| Basement Membrane | 1 | 2017 | 55 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 1999 | 451 | 0.040 |
Why?
|
| Non-Fibrillar Collagens | 1 | 1996 | 3 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 360 | 0.040 |
Why?
|
| Biopsy | 2 | 2017 | 1182 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 740 | 0.030 |
Why?
|
| Fungemia | 1 | 2015 | 15 | 0.030 |
Why?
|
| Insulin | 2 | 2014 | 1146 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 1996 | 228 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 865 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1796 | 0.030 |
Why?
|
| Collagen | 1 | 1996 | 293 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 30 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2007 | 2347 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 64 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1999 | 2880 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 118 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 1996 | 511 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 1996 | 681 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2013 | 38 | 0.030 |
Why?
|
| Urban Population | 1 | 2014 | 224 | 0.030 |
Why?
|
| Lighting | 1 | 2012 | 33 | 0.030 |
Why?
|
| Sleep, REM | 1 | 2012 | 51 | 0.030 |
Why?
|
| North Carolina | 2 | 2003 | 50 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 57 | 0.030 |
Why?
|
| Melatonin | 1 | 2012 | 50 | 0.030 |
Why?
|
| Hospital Rapid Response Team | 1 | 2012 | 27 | 0.030 |
Why?
|
| Resuscitation | 1 | 2013 | 109 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 2012 | 54 | 0.030 |
Why?
|
| Polysomnography | 1 | 2012 | 151 | 0.030 |
Why?
|
| American Heart Association | 1 | 2011 | 94 | 0.020 |
Why?
|
| Exercise | 1 | 2014 | 322 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2011 | 125 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2011 | 195 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Physician's Role | 1 | 2012 | 177 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 836 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1940 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 988 | 0.020 |
Why?
|
| Iowa | 1 | 2009 | 35 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2009 | 20 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 493 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2007 | 1591 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 207 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1067 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2011 | 899 | 0.020 |
Why?
|
| Survival Rate | 1 | 2011 | 1889 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1867 | 0.020 |
Why?
|
| Medical Staff | 1 | 2006 | 10 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 859 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2006 | 60 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 711 | 0.020 |
Why?
|
| Primary Health Care | 2 | 2002 | 351 | 0.020 |
Why?
|
| Cognition | 1 | 2010 | 580 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 434 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 502 | 0.020 |
Why?
|
| Anger | 1 | 2005 | 80 | 0.020 |
Why?
|
| Arousal | 1 | 2005 | 170 | 0.020 |
Why?
|
| Reference Values | 1 | 2005 | 661 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2005 | 293 | 0.010 |
Why?
|
| Homeostasis | 1 | 2005 | 413 | 0.010 |
Why?
|
| HLA Antigens | 2 | 1981 | 227 | 0.010 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2002 | 23 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2002 | 21 | 0.010 |
Why?
|
| Time and Motion Studies | 1 | 2002 | 21 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 2001 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1982 | 266 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1981 | 165 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 461 | 0.010 |
Why?
|
| Models, Biological | 1 | 2005 | 1764 | 0.010 |
Why?
|
| Dystonin | 1 | 1996 | 3 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1996 | 16 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1996 | 273 | 0.010 |
Why?
|
| Japan | 1 | 1996 | 303 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1996 | 374 | 0.010 |
Why?
|
| Observer Variation | 1 | 1997 | 610 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 565 | 0.010 |
Why?
|
| Clinical Competence | 1 | 1997 | 780 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 2 | 1981 | 87 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1980 | 83 | 0.000 |
Why?
|
| Celiac Disease | 1 | 1980 | 213 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1981 | 1223 | 0.000 |
Why?
|